<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03919240</url>
  </required_header>
  <id_info>
    <org_study_id>SZ4601</org_study_id>
    <nct_id>NCT03919240</nct_id>
  </id_info>
  <brief_title>CAR-T Cell Therapy Targeting to CD19 for R/R ALL</brief_title>
  <official_title>CD19-targeting Chimeric Antigen Receptor T-cell Therapy for Patients With Refractory and Relapsed B-cell Acute Lymphoblastic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital of Soochow University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The First Affiliated Hospital of Soochow University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Refractory and relapsed (R/R) acute lymphoblastic leukemia (ALL) patients with active disease
      always have a dismal outcome. Chimeric antigen receptor (CAR) T-cell therapy targeting to
      Cluster of Differentiation Antigen 19 (CD19) has been proved as a potent approach to attain
      remission in B-cell R/R patients. Therefore, the investigators conduct a trial to evaluate
      the the efficacy and safety of locally producing CAR T cells targeting CD19, and to analyze
      the outcome of enrolled B-cell ALL patients with active disease or persistent residual
      disease.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2015</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete remission</measure>
    <time_frame>1 month post infusion</time_frame>
    <description>defined as less than 5% blasts in the bone marrow without myelosuppression, no circulating blasts in peripheral blood, and the absence of extramedullary disease, regardless of cell count recovery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Minimal residual disease response</measure>
    <time_frame>1 month post infusion</time_frame>
    <description>defined as less than 0.01% bone marrow blasts assessed by multiparameter flow cytometry, and absence of genetic aberrants assessed by karyotype analysis or molecular detection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cytokine release syndrome</measure>
    <time_frame>1 month post infusion</time_frame>
    <description>grading according to the criteria proposed by Lee, et al (Blood, 2014, 124: 188-195). This grading system ranges from grade 1 (best) to grade 5 (worst), by measuring related symptoms (such as fever, nausea, fatigue, headache, etc.), oxygen requirement, blood pressure and organ toxicity (referred to CTCAE v4.0 grading)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year post infusion</time_frame>
    <description>calculating from the day of CAR T-cell infusion to death or the end of follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leukemia-free survival</measure>
    <time_frame>1 year post infusion</time_frame>
    <description>calculating from the day of CAR T-cell infusion to death, disease progression or the end of follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of relapse</measure>
    <time_frame>1 year post infusion</time_frame>
    <description>calculating from the day of CAR T-cell infusion to disease progression or the end of follow-up</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Acute Lymphoblastic Leukemia With Failed Remission</condition>
  <arm_group>
    <arm_group_label>CAR T-cell therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients enrolled will receive infusion of CD19-targeting CAR T-cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CAR T-cell therapy</intervention_name>
    <description>Patients enrolled will receive infusion of CD19-targeting CAR T-cells with a target dose of 5~10×10E6/kg of recipient weight, after the preparative regimen consisted of fludarabin (30mg/m2, day -5 to -3) and cyclophosphamide (300mg/m2, day -5 to -3).</description>
    <arm_group_label>CAR T-cell therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed as CD19+ B-cell acute lymphoblastic leukemia;

          -  Fail to achieve remission, or with persistent residual disease after at least 2 cycles
             of consolidation;

          -  With an estimated survival of higher than 3 months (according to investigator's
             judgement);

          -  Sufficient organ function: left ventricular ejection fractions≥ 0.5 by
             echocardiography, creatinine &lt; 1.6 mg/dL, aspartate aminotransferase/aspartate
             aminotransferase &lt; 3 x upper limit of normal, bilirubin &lt;2.0 mg/dL;

          -  Karnofsky performance status ≥ 60 or ECOG ≤ 2.

        Exclusion Criteria:

          -  Intolerant to immunosuppressive chemotherapies;

          -  With active infection or other uncontrolled complications;

          -  With history of seizure;

          -  Active hepatitis B or hepatitis C infection and HIV infection;

          -  Pregnant or lactating women, or patients refusing to take effective contraception
             measures;

          -  Other contraindications that considered inappropriate to participate in this trial
             (according to investigator's judgement).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Depei Wu, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Soochow University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jia Chen, M.D., Ph.D.</last_name>
    <phone>+86 512 67781856</phone>
    <email>drchenjia@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiang Zhang, M.D.</last_name>
    <phone>+86 512 67781856</phone>
    <email>lcsy2013@sina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Fisrt Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Depei Wu, M.D., Ph.D.</last_name>
      <phone>+86 512 6778 1856</phone>
      <email>wudepei@medmail.com.cn</email>
    </contact>
    <contact_backup>
      <last_name>Jia Chen, M.D.</last_name>
      <phone>+86 512 6778 1856</phone>
      <email>chenjia@suda.edu.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Depei Wu, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jia Chen, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aining Sun, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Huiying Qiu, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiaowen Tang, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yue Han, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zhengming Jin, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chengcheng Fu, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Feng Chen, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiao Ma, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Suning Chen, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiang Zhang, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95. doi: 10.1182/blood-2014-05-552729. Epub 2014 May 29. Erratum in: Blood. 2015 Aug 20;126(8):1048. Dosage error in article text. Blood. 2016 Sep 15;128(11):1533.</citation>
    <PMID>24876563</PMID>
  </reference>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 15, 2019</study_first_submitted>
  <study_first_submitted_qc>April 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2019</study_first_posted>
  <last_update_submitted>June 29, 2020</last_update_submitted>
  <last_update_submitted_qc>June 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Lymphoblastic Leukemia</keyword>
  <keyword>Refractory and relapsed</keyword>
  <keyword>Chimeric antigen receptor T-cell therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

